MedDataX Logo

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

NCT ID: NCT03758612

Last Updated: 2024-12-09

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

86 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-16

Study Completion Date

2020-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Partially-Blinded, Placebo-Controlled, Randomized, Single Ascending Dose (SAD) with a Food Effect Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study was a partially-blinded, placebo-controlled, randomized SAD study conducted at one study center. The primary objective of the study was to evaluate the safety and tolerability of single doses of TBI-223 oral suspension, TBI-223 oral enteric capsules, and TBI-223 tablet formulations in healthy adult subjects. The secondary objectives of the study were to determine the PK of TBI-223 and its metabolite M2 after single doses of TBI-223 oral suspension, TBI-223 oral enteric capsules, and TBI-223 tablet formulations in healthy adult subjects, and to compare the rate and extent of absorption of a single dose of TBI-223 oral suspension and TBI-223 tablet formulations when administered in healthy adult subjects either after a high-calorie, high-fat meal or in the fasting state.

Safety was assessed throughout the study for all subjects. Safety assessments included physical examinations, vital signs, serial ECGs, cardiac monitoring, adverse events (AEs), and clinical laboratory tests (including hematology, serum chemistry, coagulation, and urinalysis).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis Tuberculosis, Pulmonary

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

TB Tuberculosis TBI-223 Pulmonary Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators
This study is partially blinded. The repeat cohort (3b) using a different dosage formulation in Part 1 and subjects in Part 2 will be non-randomized and unblinded.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TBI-223 50 mg

Cohort 1, single dose of TBI-223 50 mg dosed under fasted conditions

Group Type ACTIVE_COMPARATOR

TBI-223 oral suspension

Intervention Type DRUG

TBI-223 oral suspension, orally administered.

TBI-223 100 mg

Cohort 2, single dose of TBI-223 100 mg dosed under fasted conditions

Group Type ACTIVE_COMPARATOR

TBI-223 oral suspension

Intervention Type DRUG

TBI-223 oral suspension, orally administered.

TBI-223 300 mg

Cohort 3a, Period 1 - gave a single dose of TBI-223 300 mg oral suspension dosed under fasted conditions.

Cohort 3b, Period 2 - participants in cohort 3a were invited after a washout period to return for an additional single dose of TBI-223 300 mg enteric capsule dosed under fasted conditions

Group Type ACTIVE_COMPARATOR

TBI-223 oral suspension

Intervention Type DRUG

TBI-223 oral suspension, orally administered.

TBI-223 enteric capsule

Intervention Type DRUG

TBI-223 enteric capsules filled with 150 mg of TBI-223 powder, orally administered.

TBI-223 600 mg

Cohort 4, single dose of TBI-223 600 mg dosed under fasted conditions

Group Type ACTIVE_COMPARATOR

TBI-223 oral suspension

Intervention Type DRUG

TBI-223 oral suspension, orally administered.

TBI-223 1200 mg

Cohort 5, Period 1, single dose of TBI-223 1200 mg dosed under fasted conditions.

Cohort 5, Period 2, participants were invited to return after a washout period to continue in period 2 and receive a single dose of TBI-223 1200 mg dosed under fed conditions

Group Type ACTIVE_COMPARATOR

TBI-223 oral suspension

Intervention Type DRUG

TBI-223 oral suspension, orally administered.

TBI-223 2000 mg

Cohort 6, single dose of TBI-223 2000 mg dosed under fasted conditions

Group Type ACTIVE_COMPARATOR

TBI-223 oral suspension

Intervention Type DRUG

TBI-223 oral suspension, orally administered.

TBI-223 2600 mg

Cohort 7, single dose of TBI-223 2600 mg dosed under fasted conditions

Group Type ACTIVE_COMPARATOR

TBI-223 oral suspension

Intervention Type DRUG

TBI-223 oral suspension, orally administered.

TBI-223 placebo

Period 1 Single dose matching placebo for TBI-223 under fasted conditions for cohorts 1 to 7

Period 2 Placebo participants in cohort 5 were invited to return after a washout period and were administered a single dose matching placebo for TBI-223 1200mg under fed conditions

Group Type PLACEBO_COMPARATOR

Placebo suspension

Intervention Type DRUG

Placebo for TBI-223 oral Suspension; orally administered.

TBI-223 3x600 mg SR-1 tablet

Cohort 8, arm 1 - Single dose TBI-223 of 1800 mg (3 x 600 mg) sustained release (SR) tablet formulation 1 under fed conditions

Group Type ACTIVE_COMPARATOR

TBI-223 SR Tablet Prototype 1

Intervention Type DRUG

TBI-223 600 mg sustained-release (SR) tablet Prototype 1, orally administered.

TBI-223 3x600 mg SR-2 tablet

Cohort 8, arm 2 - Single dose TBI-223 of 1800 mg (3 x 600 mg) sustained release (SR) tablet formulation 2 under fed conditions

Group Type ACTIVE_COMPARATOR

TBI-223 SR Tablet Prototype 2

Intervention Type DRUG

TBI-223 600 mg SR tablet Prototype 2, orally administered.

TBI-223 2x900 mg SR-3 tablet

Cohort 8, arm 3 - Single dose TBI-223 of 1800 mg (2 x 900 mg) sustained release (SR) tablet formulation 3 under fed conditions

Group Type ACTIVE_COMPARATOR

TBI-223 SR Tablet Prototype 3

Intervention Type DRUG

TBI-223 900 mg SR tablet Prototype 3, orally administered.

TBI-223 2x1000 mg IR tablet

Cohort 8, arm 4 - Single dose TBI-223 of 2000 mg (2 x 1000 mg) immediate release (IR) tablet under fasted conditions

Cohort 9 - Participants from cohort 8 arm 4 were invited to return and were administered a single dose TBI-223 of 2000 mg (2 x 1000 mg) immediate release (IR) tablet under fed conditions

Group Type ACTIVE_COMPARATOR

TBI-223 IR Tablet

Intervention Type DRUG

TBI-223 1000 mg immediate release (IR) tablet, orally administered

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TBI-223 oral suspension

TBI-223 oral suspension, orally administered.

Intervention Type DRUG

TBI-223 enteric capsule

TBI-223 enteric capsules filled with 150 mg of TBI-223 powder, orally administered.

Intervention Type DRUG

TBI-223 SR Tablet Prototype 1

TBI-223 600 mg sustained-release (SR) tablet Prototype 1, orally administered.

Intervention Type DRUG

TBI-223 SR Tablet Prototype 2

TBI-223 600 mg SR tablet Prototype 2, orally administered.

Intervention Type DRUG

TBI-223 SR Tablet Prototype 3

TBI-223 900 mg SR tablet Prototype 3, orally administered.

Intervention Type DRUG

TBI-223 IR Tablet

TBI-223 1000 mg immediate release (IR) tablet, orally administered

Intervention Type DRUG

Placebo suspension

Placebo for TBI-223 oral Suspension; orally administered.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

All volunteers must satisfy the following criteria to be considered for study participation:

1. Is a healthy adult male or female, 19 to 50 years of age (inclusive) at the time of screening.
2. Has a body mass index (BMI) ≥18.5 and ≤32.0 (kg/m2) and a body weight of no less than 50.0 kg.
3. Is medically healthy with no clinically significant screening results (e.g., laboratory profiles normal or up to Grade 1 per Division of Microbiology and Infectious Diseases Toxicity Tables), as deemed by the Investigator.
4. Has not used tobacco- or nicotine-containing products (including smoking cessation products), for a minimum of 6 months before dosing.
5. If assigned to receive study drug under fed conditions, is willing and able to consume the entire high-calorie, high-fat breakfast meal in the timeframe required.

Exclusion Criteria

1. History or presence of clinically significant cardiovascular (heart murmur), pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.
2. Any presence of musculoskeletal toxicity (severe tenderness with marked impairment of activity, or frank necrosis).
3. Has a positive test for hepatitis B surface antigen, hepatitis C antibody, or HIV at screening.
4. QTcF interval \>450 msec for males or \>470 msec for females at screening, Day -1, or Day 1 (predose), or history of prolonged QT syndrome. For the triplicate 12-lead ECGs taken at screening and on Day -1, the average QTcF interval of the three 12-lead ECG recordings were used to determine qualification.
5. Family history of long-QT syndrome or sudden death without a preceding diagnosis of a condition that was causative of sudden death (such as known coronary artery disease, congestive heart failure, or terminal cancer).
6. History of any of the following:

* Serotonin syndrome
* Seizures or seizure disorders, other than childhood febrile seizures
* Brain surgery
* History of head injury in the last 5 years
* Any serious disorder of the nervous system particularly one that lowered the seizure threshold.
7. Lactose intolerant.
8. History of sensitivity or contraindication to use of linezolid, tedizolid, or any study investigational products
Minimum Eligible Age

19 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Global Alliance for TB Drug Development

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jerry Nedelman

Role: STUDY_CHAIR

Global Alliance for TB Drug Development

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Worldwide Clinical Trials (WCT)

San Antonio, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Lombardi A, Pappas F, Bruinenberg P, Nedelman J, Taneja R, Hickman D, Beumont M, Sun E. Pharmacokinetics, tolerability, and safety of TBI-223, a novel oxazolidinone, in healthy participants. Antimicrob Agents Chemother. 2025 Apr 2;69(4):e0154224. doi: 10.1128/aac.01542-24. Epub 2025 Mar 11.

Reference Type DERIVED
PMID: 40067046 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TBI-223-CL-001

Identifier Type: -

Identifier Source: org_study_id